X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS SANOFI INDIA DR. DATSONS LABS/
SANOFI INDIA
 
P/E (TTM) x -10.9 33.6 - View Chart
P/BV x 0.2 6.4 2.5% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 DR. DATSONS LABS   SANOFI INDIA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
SANOFI INDIA
Dec-16
DR. DATSONS LABS/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1264,560 2.8%   
Low Rs314,400 0.7%   
Sales per share (Unadj.) Rs133.01,028.5 12.9%  
Earnings per share (Unadj.) Rs0.2129.0 0.1%  
Cash flow per share (Unadj.) Rs6.6186.0 3.6%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs128.8753.6 17.1%  
Shares outstanding (eoy) m31.6623.03 137.5%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.64.4 13.5%   
Avg P/E ratio x516.134.7 1,485.7%  
P/CF ratio (eoy) x11.824.1 49.2%  
Price / Book Value ratio x0.65.9 10.2%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m2,477103,174 2.4%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m563,592 1.6%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m4,21123,686 17.8%  
Other income Rs m79708 11.1%   
Total revenues Rs m4,28924,394 17.6%   
Gross profit Rs m5695,281 10.8%  
Depreciation Rs m2041,313 15.6%   
Interest Rs m43015 2,868.0%   
Profit before tax Rs m134,661 0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m61,691 0.4%   
Profit after tax Rs m52,970 0.2%  
Gross profit margin %13.522.3 60.6%  
Effective tax rate %48.036.3 132.4%   
Net profit margin %0.112.5 0.9%  
BALANCE SHEET DATA
Current assets Rs m6,85215,673 43.7%   
Current liabilities Rs m6,7116,678 100.5%   
Net working cap to sales %3.338.0 8.8%  
Current ratio x1.02.3 43.5%  
Inventory Days Days16176 211.7%  
Debtors Days Days31822 1,427.3%  
Net fixed assets Rs m3,6738,098 45.4%   
Share capital Rs m317230 137.5%   
"Free" reserves Rs m3,76117,088 22.0%   
Net worth Rs m4,07817,356 23.5%   
Long term debt Rs m1,6710-   
Total assets Rs m12,63325,400 49.7%  
Interest coverage x1.0311.7 0.3%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.30.9 35.7%   
Return on assets %3.411.8 29.3%  
Return on equity %0.117.1 0.7%  
Return on capital %7.726.9 28.5%  
Exports to sales %22.924.5 93.5%   
Imports to sales %14.328.0 51.1%   
Exports (fob) Rs m9645,801 16.6%   
Imports (cif) Rs m6026,627 9.1%   
Fx inflow Rs m9647,145 13.5%   
Fx outflow Rs m6076,846 8.9%   
Net fx Rs m357299 119.4%   
CASH FLOW
From Operations Rs m1,3453,226 41.7%  
From Investments Rs m-2,256-1,555 145.1%  
From Financial Activity Rs m-1,200-1,818 66.0%  
Net Cashflow Rs m-2,111-147 1,435.9%  

Share Holding

Indian Promoters % 4.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.0 14.4 -  
FIIs % 1.4 14.6 9.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 10.5 896.2%  
Shareholders   20,807 15,184 137.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

Khadim India Ltd. (IPO)

Oct 31, 2017

Should you subscribe to the IPO of Khadim India Ltd?

Mahindra Logistics Ltd. (IPO)

Oct 28, 2017

Should you subscribe to the IPO of Mahindra Logistics Ltd?

Godrej Agrovet Ltd. (IPO)

Oct 4, 2017

Should you subscribe to the IPO of Godrej Agrovet Limited?

Matrimony.com (IPO)

Sep 11, 2017

Should you subscribe to the IPO of Matrimony.com?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS